TY - JOUR
T1 - Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab
AU - Gentile, Massimo
AU - Shanafelt, Tait D.
AU - Reda, Gianluigi
AU - Mauro, Francesca Romana
AU - Zirlik, Katja
AU - Ciolli, Stefania
AU - Laurenti, Luca
AU - Del Principe, Maria Ilaria
AU - Rossi, Davide
AU - Di Renzo, Nicola
AU - Molica, Stefano
AU - Angrilli, Francesco
AU - Coscia, Marta
AU - Chiarenza, Annalisa
AU - Giordano, Annamaria
AU - Cutrona, Giovanna
AU - Chaffee, Kari G.
AU - Parikh, Sameer A.
AU - Uccello, Giuseppina
AU - Innocenti, Idanna
AU - Tripepi, Giovanni
AU - D’Arrigo, Graziella
AU - Vigna, Ernesto
AU - Recchia, Anna Grazia
AU - Herishanu, Yair
AU - Shvidel, Lev
AU - Tadmor, Tamar
AU - Cortelezzi, Agostino
AU - Del Poeta, Giovanni
AU - Gaidano, Gianluca
AU - Di Raimondo, Francesco
AU - Neri, Antonino
AU - Ferrarini, Manlio
AU - Foà, Robin
AU - Foa, Robin
AU - Polliack, Aaron
AU - Morabito, Fortunato
PY - 2018
Y1 - 2018
N2 - During the the last two decades several biological prognostic markers have been identified in chronic lymphocytic leukemia (CLL) [1]. Some, like the IGHV mutational status and TP53 disruption, are also predictive of response to chemo-immunotherapy [2,3,4,5,6]. Rossi et al. reported an observational retrospective analysis on 404 CLL patients treated front-line with fludarabine-cyclophosphamide-rituximab (FCR) [6]. Based on the IGHV mutational status and FISH cytogenetics, patients were stratified into low risk (mutated IGHV and no adverse FISH cytogenetics [del(17p), del(11q)]), intermediate risk (unmutated IGHV and/or del11q in the absence of del17p), and high risk (del17p independent of co-occurring del11q or unmutated IGHV). This simple biologically based prognostic score based on the combination of three widely utilized biomarkers allowed to stratify patients with a significantly different progression-free survival (PFS) and overall survival (OS) after FCR treatment. In addition, they also demonstrated that low-risk patients had a durable remissions after FCR, with a life expectancy overlapping that observed in the age-matched general population [6]. Similarly, Laurenti et al. recently published a retrospective study on 102 patients with CLL treated front-line with chlorambucil-rituximab [7]. This analysis also showed that the above-mentioned biological score could distinguish patients with a different PFS. A trend toward a better OS was also observed.
AB - During the the last two decades several biological prognostic markers have been identified in chronic lymphocytic leukemia (CLL) [1]. Some, like the IGHV mutational status and TP53 disruption, are also predictive of response to chemo-immunotherapy [2,3,4,5,6]. Rossi et al. reported an observational retrospective analysis on 404 CLL patients treated front-line with fludarabine-cyclophosphamide-rituximab (FCR) [6]. Based on the IGHV mutational status and FISH cytogenetics, patients were stratified into low risk (mutated IGHV and no adverse FISH cytogenetics [del(17p), del(11q)]), intermediate risk (unmutated IGHV and/or del11q in the absence of del17p), and high risk (del17p independent of co-occurring del11q or unmutated IGHV). This simple biologically based prognostic score based on the combination of three widely utilized biomarkers allowed to stratify patients with a significantly different progression-free survival (PFS) and overall survival (OS) after FCR treatment. In addition, they also demonstrated that low-risk patients had a durable remissions after FCR, with a life expectancy overlapping that observed in the age-matched general population [6]. Similarly, Laurenti et al. recently published a retrospective study on 102 patients with CLL treated front-line with chlorambucil-rituximab [7]. This analysis also showed that the above-mentioned biological score could distinguish patients with a different PFS. A trend toward a better OS was also observed.
KW - CLL
KW - CLL
UR - http://hdl.handle.net/10807/135114
U2 - 10.1038/s41375-018-0100-6
DO - 10.1038/s41375-018-0100-6
M3 - Article
SN - 0887-6924
VL - 32
SP - 1869
EP - 1873
JO - Leukemia
JF - Leukemia
ER -